Scientists in labs will keep making exciting discoveries about how psychedelics affect the brain in 2026, mostly using animal studies and new research tools. But turning those discoveries into treatments proven to work safely in humans takes much longer. This gap between 'what we're finding in the lab' and 'what we can actually offer patients' will stay wide.
Today's signals are rat models and methods development, not Phase 3 confirmations. The neuroscience races ahead while durable clinical proof lags.
Join our community — a free weekly Zoom circle with a master facilitator. Come sit with us first; the rest reveals itself.
Join the Free Weekly Circle →